Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort.

Annals of hematology - 1 Mar 2017

Ianotto Jean-Christophe, Chauveau Aurélie, Mottier Dominique, Ugo Valérie, Berthou Christian, Lippert Eric, Delluc Aurélien

Abstract excerpt

Cancer incidence in patients with recurrent unprovoked venous thromboembolism (VTE) is much higher than after a first event, but the incidence of myeloproliferative neoplasms (MPN) in this situation is still unknown. We tested for JAK2V617F and calreticulin mutants, 372 DNA samples of patients treated for (VTR). Among these patients, 10 (2.7%) were carrying JAK2V617F mutation and none of them any of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Calbindin 2

Share to Cohort Studies

Share to Follow-Up Studies

Share to Janus Kinase 2

Share to Recurrence

Share to Venous Thromboembolism

Source

Identifiers

PMID: 27766390
DOI: 10.1007/s00277-016-2853-1

Genes

CALR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort.PMID 27766390Read ↗

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.Semantic proximity Read ↗

Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients.Semantic proximity Read ↗

Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis.Semantic proximity Read ↗

Analysis of CALR-mutated essential thrombocythemia as a distinct disease entity compared with JAK2 V617F-mutated and triple-negative patients.Semantic proximity Read ↗

Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.Semantic proximity Read ↗

Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general populationSemantic proximity Read ↗

Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.Semantic proximity Read ↗

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.Semantic proximity Read ↗

[Clinical and biological features of patients with essential thrombocythaemia according to their mutational status JAK2 or CALR: Single-center study of 40 patients and review of the literature].Semantic proximity Read ↗

Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia.Semantic proximity Read ↗

Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosisSemantic proximity Read ↗

A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.